StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

RVMDBullishAnalyst Target Updateanalyst
Medium materiality6/10

H.C. Wainwright Reiterates Buy on Revolution Medicines

Nov 17, 2026, 10:08 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The large target-implied upside is notable, but this is a reiterated rating from one analyst and should be treated as an opinion rather than a forecast.

AI summary

What happened, with direct paths to the underlying reporting

H.C. Wainwright reiterated its Buy rating on RVMD with a $350 target, about 110% above the posted price of $166.87.

  • H.C. Wainwright reiterated Buy and a $350 target for RVMD.
  • The target is about 110% above the posted price.

Key facts

  1. 01

    Target: $350

  2. 02

    Posted price: $166.87

  3. 03

    Analyst firm: H.C. Wainwright

  4. 04

    Analyst: Raghuram Selvaraju

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.